JP2022515272A5 - - Google Patents
Info
- Publication number
- JP2022515272A5 JP2022515272A5 JP2021537128A JP2021537128A JP2022515272A5 JP 2022515272 A5 JP2022515272 A5 JP 2022515272A5 JP 2021537128 A JP2021537128 A JP 2021537128A JP 2021537128 A JP2021537128 A JP 2021537128A JP 2022515272 A5 JP2022515272 A5 JP 2022515272A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- sodium
- group
- mixture
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024199593A JP2025032127A (ja) | 2018-12-24 | 2024-11-15 | ピロロピリミジン化合物の治療的使用およびその固形医薬組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811581815.8 | 2018-12-24 | ||
| CN201811581815 | 2018-12-24 | ||
| CN201910679429 | 2019-07-26 | ||
| CN201910679429.0 | 2019-07-26 | ||
| PCT/CN2019/127837 WO2020135401A1 (zh) | 2018-12-24 | 2019-12-24 | 吡咯并嘧啶化合物的治疗用途及其固体药物组合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024199593A Division JP2025032127A (ja) | 2018-12-24 | 2024-11-15 | ピロロピリミジン化合物の治療的使用およびその固形医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022515272A JP2022515272A (ja) | 2022-02-17 |
| JP2022515272A5 true JP2022515272A5 (enExample) | 2023-01-06 |
Family
ID=71126879
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021537128A Pending JP2022515272A (ja) | 2018-12-24 | 2019-12-24 | ピロロピリミジン化合物の治療的使用およびその固形医薬組成物 |
| JP2024199593A Pending JP2025032127A (ja) | 2018-12-24 | 2024-11-15 | ピロロピリミジン化合物の治療的使用およびその固形医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024199593A Pending JP2025032127A (ja) | 2018-12-24 | 2024-11-15 | ピロロピリミジン化合物の治療的使用およびその固形医薬組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220072002A1 (enExample) |
| EP (1) | EP3904356A4 (enExample) |
| JP (2) | JP2022515272A (enExample) |
| KR (1) | KR20210132007A (enExample) |
| CN (2) | CN113242859B (enExample) |
| AU (1) | AU2019413421B9 (enExample) |
| CA (1) | CA3123985A1 (enExample) |
| WO (1) | WO2020135401A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023548855A (ja) * | 2020-11-05 | 2023-11-21 | エグゼリクシス， インコーポレイテッド | キナーゼ阻害剤の医薬組成物 |
| CN118973582A (zh) * | 2022-03-21 | 2024-11-15 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物治疗中高危骨髓纤维化的用途 |
| WO2024153148A1 (zh) * | 2023-01-18 | 2024-07-25 | 北京普祺医药科技股份有限公司 | 一种杂环化合物、药物组合物及其用途 |
| WO2024230727A1 (zh) * | 2023-05-09 | 2024-11-14 | 正大天晴药业集团股份有限公司 | 一种吡咯并[2,3-c]吡啶酮化合物的联用药物组合物及其用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0775204A1 (en) * | 1994-08-09 | 1997-05-28 | Novartis AG | Antitumor antisense oligonucleotides |
| PL351069A1 (en) * | 1999-12-08 | 2003-03-10 | Pharmacia Corp | Valdecoxib compositions |
| US20070054848A1 (en) * | 2003-03-28 | 2007-03-08 | Masaya Tohyama | Composition and method for nerve regeneration |
| US20050130302A1 (en) * | 2003-09-29 | 2005-06-16 | Reprocell Inc. | Method and composition for regulating expansion of stem cells |
| WO2007089926A2 (en) * | 2006-01-31 | 2007-08-09 | Teva Pharmaceutical Industries Ltd. | Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution |
| KR101566840B1 (ko) * | 2007-03-12 | 2015-11-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| AR076794A1 (es) * | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| EP3354652B1 (en) * | 2010-03-10 | 2020-05-06 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| PH12013502523A1 (en) * | 2011-06-14 | 2019-10-11 | Novartis Ag | Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm |
| NZ714502A (en) * | 2011-07-05 | 2017-04-28 | Vertex Pharma | Processes and intermediates for producing azaindoles |
| CN104418858B (zh) * | 2013-08-30 | 2018-12-11 | 浙江医药股份有限公司新昌制药厂 | 2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用 |
| CN103585126A (zh) * | 2013-11-18 | 2014-02-19 | 南京艾德凯腾生物医药有限责任公司 | 一种托法替尼组合物及制备方法 |
| NZ723859A (en) * | 2014-03-14 | 2023-01-27 | Servier Lab | Pharmaceutical compositions of therapeutically active compounds and their uses |
| AU2015276857B2 (en) * | 2014-06-20 | 2017-10-19 | Vaxart, Inc. | Anhydrous crystalline free base form of-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzisoxazole |
| CN105777754B (zh) * | 2014-12-16 | 2019-07-26 | 北京赛林泰医药技术有限公司 | 吡咯并嘧啶化合物 |
| KR101964546B1 (ko) * | 2015-07-27 | 2019-04-01 | 유니켐 레버러토리스 리미티드 | 토파시티닙 경구 붕해 정제 |
| CN108368115B (zh) * | 2015-12-15 | 2020-01-03 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物的盐 |
| CN107334738B (zh) * | 2016-04-28 | 2021-02-09 | 天津科伦药物研究有限公司 | 一种含巴瑞克替尼的药物组合物及其制备方法和用途 |
| CN107759600A (zh) | 2016-06-16 | 2018-03-06 | 正大天晴药业集团股份有限公司 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
| CN107513069A (zh) * | 2016-06-16 | 2017-12-26 | 正大天晴药业集团股份有限公司 | 手性吡咯并嘧啶化合物的制备方法 |
| CN107513067A (zh) * | 2016-06-16 | 2017-12-26 | 北京赛林泰医药技术有限公司 | 含有取代环戊基的吡咯并嘧啶化合物 |
| HRP20240112T1 (hr) * | 2017-03-14 | 2024-04-12 | Galapagos Nv | Farmaceutske tvari koje uključuju inhibitor janus kinaze (jak) |
| WO2018204787A1 (en) * | 2017-05-05 | 2018-11-08 | Memorial Sloan Kettering Cancer Center | Methods of treatment of myeloproliferative neoplasm |
| US12447154B2 (en) * | 2020-03-09 | 2025-10-21 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Use of pyrrolopyrimidine compound for treating hemophagocytic syndrome |
| CA3222218A1 (en) * | 2021-06-21 | 2022-12-29 | Lifan TU | Use of pyrrolopyrimidine compound and pharmaceutical composition thereof for treating chronic graft versus host disease |
-
2019
- 2019-12-24 CA CA3123985A patent/CA3123985A1/en active Pending
- 2019-12-24 WO PCT/CN2019/127837 patent/WO2020135401A1/zh not_active Ceased
- 2019-12-24 EP EP19905962.7A patent/EP3904356A4/en active Pending
- 2019-12-24 KR KR1020217023608A patent/KR20210132007A/ko not_active Ceased
- 2019-12-24 US US17/417,712 patent/US20220072002A1/en active Pending
- 2019-12-24 AU AU2019413421A patent/AU2019413421B9/en active Active
- 2019-12-24 CN CN201980081492.2A patent/CN113242859B/zh active Active
- 2019-12-24 JP JP2021537128A patent/JP2022515272A/ja active Pending
- 2019-12-24 CN CN202310447777.1A patent/CN116473973A/zh active Pending
-
2024
- 2024-11-15 JP JP2024199593A patent/JP2025032127A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022515272A5 (enExample) | ||
| RU2445095C2 (ru) | Новые фармацевтические композиции для лечения сексуальных расстройств | |
| JP6875407B2 (ja) | Ｊａｋキナーゼ阻害剤またはその薬剤的に許容される塩を含有する医薬組成物 | |
| RU2014115427A (ru) | Фармацевтические композиции замещенных хиназолинонов | |
| KR101041203B1 (ko) | 안정한 이매티닙 조성물 | |
| JP2014532638A5 (enExample) | ||
| JP2023116489A5 (enExample) | ||
| RU2016144479A (ru) | Фармацевтические композиции для лечения заболеваний, опосредопосредованных муковисцидозным трансмембранным регулятором проводимости | |
| HUP0303315A2 (hu) | Pirazolo [4,3-d] pirimidineket és trombózisellenes szereket, kalcium antagonistákat, prosztaglandinokat vagy prosztaglandinszármazékokat tartalmazó gyógyszerkészítmények | |
| KR20140075754A (ko) | 7-[4-(4-벤조[ｂ]티오펜-4-일-피페라진-1-일)부톡시]-1Ｈ-퀴놀린-2-온 또는 그 염을 함유하는 정제 | |
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| HUT71481A (en) | Pharmaceutical compositions for treatment of seborrea and acne containing 2-phenyl-3-aroyl-benzothiophene derivatives and process for their preparation | |
| JP2006503875A5 (enExample) | ||
| MX2021012684A (es) | Composiciones farmaceuticas estables y conservadas de bilastina. | |
| MD523G2 (ro) | Derivaţi noi ai triazolpirimidinei, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice ce le conţin | |
| HRP20151051T1 (hr) | Formulacije src/abl inhibitora | |
| JP4542777B2 (ja) | 肺高血圧症を予防または治療するのに用いられる医薬の製造のためのイルベサルタンの使用 | |
| JP2020511437A5 (enExample) | ||
| RU2021119947A (ru) | Лечебное применение пирролопиримидинового соединения и твердая фармацевтическая композиция пирролопиримидинового соединения | |
| JPH0597827A (ja) | 新規の薬学活性成分としての２−イミノチアゾリジン−４−オン誘導体 | |
| KR101524264B1 (ko) | 발사르탄 함유 경구용 약학 조성물 | |
| JP2024524933A5 (enExample) | ||
| HUP0002643A2 (hu) | Szívrendellenességek kezelése és megelőzése SSRI-k alkalmazásával | |
| CZ2003945A3 (cs) | Farmaceutický prostředek | |
| JPH05262747A (ja) | 潰瘍性大腸炎治療剤 |